Mutations and aberrant activation of JAKs have been implicated in various types of cancers. For instance, JAK2 V617F mutation is frequently found in myeloproliferative disorders like polycythemia vera, essential thrombocythemia, and primary myelofibrosis. These mutations lead to uncontrolled cell proliferation and survival, contributing to oncogenesis. Abnormal JAK activity also results in increased cytokine production, which can create a tumor-promoting microenvironment.
